| CAS NO: | 832720-36-2 |
| 包装 | 价格(元) |
| 10 mM * 1 mL in DMSO | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 500mg | 电议 |
| 生物活性 | Elagolix sodium is a humanGnRH receptor(GnRHR) antagonist with anIC50andKiof 0.25 and 3.7 nM, respectively. | ||||||||||||||||
| IC50& Target | IC50: 0.25 nM (GnRHR)[1]Ki: 3.7 nM (GnRHR)[2] | ||||||||||||||||
| 体外研究 (In Vitro) | Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC50of 0.25 nM in Kinase assay. Elagolix sodium has advanced to phase 3 trials for the treatment of endometriosis and uterine fibroids. Elagolix sodium also shows NFAT inhibition with an IC50of 5.4 nM and effectively blocks Ca2+flux with an IC50of 0.86 nM[1]. Kinase assay also demonstrates that Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with a Kivalue of 3.7 nM[2]. | ||||||||||||||||
| Clinical Trial | |||||||||||||||||
| 分子量 | 653.57 | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| Formula | C32H29F5N3NaO5 | ||||||||||||||||
| CAS 号 | 832720-36-2 | ||||||||||||||||
| 中文名称 | 恶拉戈利钠杂质27 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
| 溶解性数据 | In Vitro: DMSO : 50 mg/mL(76.50 mM;Need ultrasonic) H2O : ≥ 50 mg/mL(76.50 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
